Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003549 · ClinicalTrials.gov registry record · Phase 2
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00003549 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 80 participants.
The verdict
NCT00003549, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.
Interventions
- DRUG cyclophosphamide
- DRUG fluorouracil
- DRUG methotrexate
- DRUG CMF regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1998-10 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003549
The ClinicalTrials.gov registry entry for NCT00003549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00003549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003549 about?
NCT00003549 is a clinical study titled "S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treatin...
What is the current status of trial NCT00003549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1998-10. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00003549?
The interventions under investigation include: cyclophosphamide (DRUG), fluorouracil (DRUG), methotrexate (DRUG), CMF regimen (DRUG).
Who is sponsoring clinical trial NCT00003549?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.